Nabi Biopharmaceuticals

Nabi Biopharmaceuticals develops and markets products that target serious medical conditions in the areas of transplantation, infectious disease, nicotine addiction, and hematology/oncology. The company’s products under development include ATG Fresenius-S, a Phase III clinical trial product for acute lung transplant rejection; IVIG and other Plasma fractions under pre-clinical development for various immune deficiencies and coagulation disease; and StaphVAX for protection against types 5 and 8 S. aureus infections. Its products under development also include Altastaph for treatment and/or protection of types 5 and 8 S. aureus infections; S. aureus 336 and S. epidermidis vaccine and corresponding antibodies for protection against S. epidermidis and type 336 infections; Panton-Valentine Leukocidin under preclinical development for the protection and/or treatment against the PVL toxin; Alpha Toxin for protection and/or treatment against the S.aureus alpha toxin; NicVAX, a Phase IIb clinical trial product for treatment of nicotine addiction; and Anti-D product, a polyclonal antibody under pre-clinical development for treatment of immune thrombocytopenic purpura. In addition, Nabi Biopharmaceuticals offers contract manufacturing services primarily to research and development-stage companies. Nabi Biopharmaceuticals serves wholesalers, distributors, hospitals, home healthcare companies, pharmaceutical and diagnostic product manufacturers. It has strategic alliances with Novartis, Talecris Biotheraputics, ProMetic, and Fresenius Biotech. The company was founded in 1967 and is headquartered in Rockville, Maryland.